$15.960
-0.661 (-4.14%)Al cierre
- High
- 16.560
- Open
- 16.170
- VWAP
- 16.12
- Vol
- 237.14K
- Mkt Cap
- 16.65M
- Low
- 15.844
- Amount
- 3.82M
- EV/EBITDA, TTM
- -0.46
Cara Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery, development, and commercialization of novel therapeutics to treat serious medical conditions, including pruritus. The Company’s KORSUVA (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis (HD). Its novel compound, difelikefalin, is a highly selective, primarily peripherally acting kappa opioid receptor (KOR) agonist. The Company is developing an oral formulation of difelikefalin and has Phase III programs ongoing for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease (NDD-CKD), and atopic dermatitis (AD). In addition, the Company has initiated a Phase II/III program of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica (NP).
Analyst Ratings (7)
Needham
—
2024-06-13
Needham
2024-06-13
Precio objetivo
—
HC Wainwright & Co.
—
2024-06-13
HC Wainwright & Co.
2024-06-13
Precio objetivo
—
Canaccord Genuity
$1
2024-06-13
Canaccord Genuity
2024-06-13
Precio objetivo
$1
Needham
$5
2024-05-23
Needham
2024-05-23
Precio objetivo
$5
HC Wainwright & Co.
$3.6
2024-05-15
HC Wainwright & Co.
2024-05-15
Precio objetivo
$3.6
Métricas de valoración
Cronología de eventos
Noticias
9.507-10Yahoo FinanceCarasent AB Reports Strong Recurring Revenue Growth Amid Challenges
8.504-15Business InsiderCara Therapeutics trading halted, news pending
3.003-02SeekingAlphaEarnings week ahead: TGT, COST, CRWD, AVGO, JD, PLUG, MRVL, and more
7.002-21PRnewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BLUE, VOXX, CARA, CYTH on Behalf of Shareholders
7.002-20BusinesswireCARA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cara Therapeutics, Inc. - CARA
CARA FAQ — answered by Alphio AI
Cara Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery, development, and commercialization of novel therapeutics to treat serious medical conditions, including pruritus. The Company’s KORSUVA (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis (HD). Its novel compound, difelikefalin, is a highly selective, primarily peripherally acting kappa opioid receptor (KOR) agonist. The Company is developing an oral formulation of difelikefalin and has Phase III programs ongoing for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease (NDD-CKD), and atopic dermatitis (AD). In addition, the Company has initiated a Phase II/III program of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica (NP). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
7 analysts cover CARA: 6 rate it Buy, 1 Hold and 0 Sell.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.